Navigation Links
Isis Reports Financial Results and Highlights for Third Quarter 2010
Date:11/4/2010

e payments in the middle of this year.  When we look at the remainder of 2010, we do not anticipate receiving any significant milestone payments; therefore we expect that our revenue in the fourth quarter will be less than in earlier quarters.  Additionally in the fourth quarter, we have a number of internal drugs that are advancing in clinical development.  We will begin two Phase 2 programs for our CRP and eIF-4E drugs and two Phase 1 programs for our FXI and APOCIII drugs.  We will also expand our development pipeline.  These activities will result in an increase in our expenses in the fourth quarter.  Even with these changes, we are on track to meet or improve upon the revised guidance of a pro forma net operating loss in the mid to high $40 million range and year-end cash of more than $450 million that we announced in August."

Upcoming Key Milestones

  • Genzyme expects to file for marketing approval for mipomersen in the U.S. and E.U. in the first half of 2011
  • Report full data from the positive Phase 3 studies evaluating mipomersen in high-cholesterol patients at high risk for coronary heart disease and in patients with severe hypercholesterolemia
  • Initiate the broad Phase 2 program of ISIS-EIF4ERx in patients with cancer
  • Complete and report data from the Phase 1 study of ISIS-CRPRx and initiate the Phase 2 program
  • Excaliard to complete and report data from the remaining Phase 2 studies of EXC 001

  • Financial ResultsBeginning in the first quarter of 2010, as a result of adopting a new required accounting standard, Isis is no longer including Regulus' revenue and operating expenses in its operating results and no longer including Regulus' cash and debt on its balance sheet.  A reconciliation presenting Isis' 2009 operating results on a comparable basis to 2010 appears later in this release.

    All pro forma amounts referred to in this press release exclude non
    '/>"/>

    SOURCE Isis Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
    2. Spherix Reports Second Quarter Earnings
    3. Tapestry Reports Second Quarter 2007 Results
    4. Callisto Reports on Second-Quarter 2007 Milestones
    5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
    6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
    7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
    8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
    9. Biopure Reports on Meeting with the FDA
    10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
    11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/23/2014)...  The management team at Columbia Laboratories, Inc. ... conference call on July 31, 2014, to discuss ... 30, 2014.  The call details are as follows:Date: ... EDTDial-in numbers: , Toll free: (877) 870-4263 (U.S.), ... archive): , www.columbialabs.com , under ,Investor, or ...
    (Date:7/23/2014)... ORANGE, Calif. , July 23, 2014 ... will gather in Las Vegas ... event. Spearheaded by educator, author, forward thinker and private ... to bring experts together to candidly discuss clinical and ... two day event is a unique opportunity to welcome ...
    (Date:7/23/2014)... , July 23, 2014  Silk Road ... the transcarotid treatment of intra- and extra-cranial cerebrovascular ... P. Wallace to the position of Chief ... lead the company,s Research and Development efforts across ... Prior to joining Silk Road ...
    Breaking Medicine Technology:Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 22014 DOCtalk Registration Now Open 22014 DOCtalk Registration Now Open 3Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 2Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer 3
    ... Analyzes the Effectiveness and Safety of Statin Use for Those Who Need It , ... Recommendations for Choosing a ,Best Buy, Statin and Strategies for ... YONKERS, N.Y. , June 29 ... ) caution that the benefits of statin use by children and some women may ...
    ... Initiative Launched on Biosafety , , ... WASHINGTON , June 29 Remember chemistry sets, ham radio, amateur ... 2,000 people from around the world belong to the Do-It-Yourself Biology (DIYbio) community, ... bio-monitoring, to new treatments for diseases. , ...
    Cached Medicine Technology:Consumer Reports Health Questions Use of Statins By Children and Some Women 2Consumer Reports Health Questions Use of Statins By Children and Some Women 3Consumer Reports Health Questions Use of Statins By Children and Some Women 4Consumer Reports Health Questions Use of Statins By Children and Some Women 5Consumer Reports Health Questions Use of Statins By Children and Some Women 6Consumer Reports Health Questions Use of Statins By Children and Some Women 7Responsible Science for Do-It-Yourself Biologists 2
    (Date:7/23/2014)... July 24, 2014) If past experience is anything ... are about to get a lot more recognition for ... on the books allowing NPs to provide primary care ... care and better relationships with physicians and administrators, compared ... from Columbia University School of Nursing, published in ...
    (Date:7/23/2014)... 2014 Celebrating a decade of philanthropy ... announced the awarding of $1,070,000 in grants to 20 ... recognition of the Foundation’s 1,000th grant. , “The Horizon ... tradition of supporting community-based organizations that are working to ... in the Garden State,” said Robert A. Marino, Horizon ...
    (Date:7/23/2014)... body of research suggesting a safe and effective ... breast cancer, with fewer detrimental side effects and ... The study will be published in final format ... and Endocrinology . , Breast cancer is the ... United States. Approximately 70% of breast cancers are ...
    (Date:7/23/2014)... 23, 2014 Global Cardio Care, Inc., ... External Counterpulsation (EECP), is celebrating the 100th birthday ... at the health center. , Weber has been ... receiving ongoing EECP therapy since 1999, he no longer ... CEO of Global Cardio Care, introduced the Sara ...
    (Date:7/23/2014)... The voice on the recording was low and calm as ... was infected with the human immunodeficiency virus (HIV) that causes AIDS: ... you know I was on the floor flat on my face ... when the recording ended less than 10 minutes later. “Don’t feel ... because it is just God setting you up for something greater,” ...
    Breaking Medicine News(10 mins):Health News:New York law offers nurses more recognition, responsibility 2Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 2Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 3Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 4Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 5Health News:Hormones after breast cancer: Not fuel for the fire after all? 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 4Health News:Hormones after breast cancer: Not fuel for the fire after all? 5Health News:Global Cardio Care Celebrates EECP Patient’s 100th Birthday 2Health News:HIV clinic-based audio project emphasizes the power of patient voices 2Health News:HIV clinic-based audio project emphasizes the power of patient voices 3
    ... cancer center at NYU Langone Medical Center, identified for ... (miRNAs) play in melanoma metastasis to simultaneously cause cancer ... to fight abnormal cells. The new study is published ... Cancer Cell. Researchers performed a miRNA ...
    ... , MONDAY, July 11 (HealthDay News) -- Too much salt ... risk for cardiovascular disease and death, a new study shows. ... pressure and high levels of salt consumption and low levels ... called sodium -- and low potassium appears to convey a ...
    ... Dotinga HealthDay Reporter , MONDAY, July 11 ... in their homes face a higher risk of developing ... new study finds. The research doesn,t definitively ... it doesn,t say how much smoke is too much. ...
    ... By Denise Mann HealthDay Reporter , MONDAY, ... reduce the risk of lasting neurological damage, but this lifesaving ... local hospitals don,t have the proper systems in place, and ... arrest to be effective, according to the report in the ...
    ... DETROIT Na Zhu, a Wayne State University College ... Association Student Research Grant Program award. The program financially ... a cure for tinnitus. Zhu, a Ph.D. ... Professor in the Department of Mechanical Engineering, is developing ...
    ... that can accumulate to high levels in our body ... linked to an increased risk of cancer and/or impaired ... by Sridhar Mani, at Albert Einstein College of Medicine, ... between environmental exposure to these foreign chemicals (xenogens) and ...
    Cached Medicine News:Health News:Researchers identify key role of microRNAs in melanoma metastasis 2Health News:Study: Potassium Boosts Heart Health, Salt Harms It 2Health News:Study: Potassium Boosts Heart Health, Salt Harms It 3Health News:ADHD, Learning Issues May Be Linked to Secondhand Smoke 2Health News:Coordinated Cooling Effort After Cardiac Arrest Can Improve Outcomes 2Health News:Coordinated Cooling Effort After Cardiac Arrest Can Improve Outcomes 3
    ... The Self-Cath family of ... patients a variety of ... Each catheter is ... grade PVC and has ...
    ... The Self-Cath family of ... patients a variety of ... Each catheter is ... grade PVC and has ...
    IMMCO ANA Elisa meets the guidelines for the laboratory diagnosis and monitoring of systemic autoimmune rheumatic diseases intended for the use of clinical pathologists and laboratory physicians....
    ... is engineered to distribute contact pressure evenly over ... back, to maximize stability and patient comfort. ... readily conformable to patient anatomy, to provide a ... wool liner is standard on both units, as ...
    Medicine Products: